Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Genus shares hit new record high after upgrading guidance again

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Genus (GNS) £45.64
Gain to date: 60.4%
Original entry point: Buy at £28.46, 19 September 2019
Shares in animal genetics company Genus (GNS) reached an all-time high this week after the company upped guidance for full year growth.
Commenting on trading for the six months to 31 December 2020, Genus said it expected adjusted pre-tax profit in actual currency to be between £47 million and £49 million compared with £36.6 million in the previous year.
Revenues are expected to be in the £285 million to £287 million range, up 5% from the £270.7 million achieved in 2019. Strong trading in the pig genetics business in China continued as farmers rebuilt pig herds after the impact from African Swine fever. In addition, bovine genetics showed strength across Brazil, Russia, India and China.
While the board expects some slowdown in the second half, the momentum already gained will result in higher growth than previously expected for the year to 30 June 2021.
SHARES SAYS: The current consensus analyst estimate for full year pre-tax profit is £79.2 million on revenues of £592 million according to data provided by Refinitiv, implying upward pressure on estimates once analysts incorporate the latest update. The stock remains a ‘buy’.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.
Our website uses cookies to give you a better browsing experience.
You can choose to accept all cookies, or control which we use by clicking 'Manage cookies'. To learn more, read our cookie policy.